AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TLX · NASDAQ · Biotechnology

Telix Pharmaceuticals (TLX)

Commercializes prostate-cancer imaging agents while developing radiopharmaceutical diagnostics and treatments.

$11.28

vs last close−0.67 (−5.61%)

In millions of USD, except per-share figures · converted from AUD at the latest rate

In millions	Q4 FY20Dec 2020	Q2 FY21Jun 2021	Q4 FY21Dec 2021	Q2 FY22Jun 2022	Q4 FY22Dec 2022	Q2 FY23Jun 2023	Q4 FY23Dec 2023	Q2 FY24Jun 2024	Q4 FY24Dec 2024	Q2 FY25Jun 2025	Q4 FY25Dec 2025	Q2 FY26Jun 2026
Revenue	3	2	3	17	96	156	199	133	419	418	437	487
Cost of revenue	8	10	17	28	64	92	41	46	147	215	207	236
Gross profit	−6	−8	−13	−11	32	64	158	87	272	203	231	251
	15	14	22	34	38	42	144	78	224	192	224	265
Research & development	10	10	14	18	23	21	69	32	53	87	95	126
	12	5	7	16	45	20	49	67	79	104	129	139
Selling & marketing	1	2	2	7	19	4	18	26	34	52	0	0
General & administrative	11	3	5	9	26	16	31	41	45	51	0	0
Other expenses	−7	0	0	0	−30	0	25	−22	92	1	0	0
Operating income	−21	−22	−35	−45	−7	22	−11	10	48	11	7	−14
	−4	−4	−9	−5	−13	−31	22	−3	−15	−16	−7	44
Interest income	0	0	0	0	0	0	0	0	7	0	2	2
Interest expense	1	0	0	0	0	0	0	3	12	3	8	5
Other non-operating income	4	4	8	5	13	31	1	0	−7	12	−1	0
Income before tax	−25	−26	−44	−50	−20	−9	11	6	33	−5	0	30
Income tax expense	−6	−3	−10	0	4	1	−3	−2	6	−3	5	−9
Net income from continuing operations	−19	−23	−34	−50	−23	−10	14	21	27	−2	−5	39
Net income	−19	−23	−34	−50	−23	−10	14	8	27	−2	−5	39
EPS, basic	−$0.07	−$0.08	−$0.12	−$0.16	−$0.07	−$0.03	$0.04	$0.02	$0.08	−$0.01	−$0.02	$0.11
EPS, diluted	−$0.07	−$0.08	−$0.12	−$0.16	−$0.07	−$0.03	$0.04	$0.02	$0.08	−$0.01	−$0.02	$0.11
Weighted average shares, basic	260	281	283	307	316	318	324	334	331	337	339	339
Weighted average shares, diluted	260	281	283	307	316	318	324	351	345	337	339	357
EBITDA	−22	−24	−42	−48	−18	−6	16	28	58	6	20	12
Depreciation & amortization	2	2	2	2	2	2	1	3	3	8	13	26
EBIT	−24	−26	−44	−50	−19	−8	14	26	55	−1	8	−14